NORMOTHERMIC MACHINE PERFUSION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Global Normothermic Machine Perfusion Market Size and Forecast – 2026 to 2033

According to Coherent Market Insights, the global normothermic machine perfusion market is estimated to be valued at USD 2.05 Bn in 2026 and is expected to reach USD 6.57 Bn by 2033, expanding at a compound annual growth rate (CAGR) of 18.11% from 2026 to 2033.

Key Takeaways of the Normothermic Machine Perfusion Market

• From an application perspective, organ preservation dominates the global normothermic machine perfusion market, accounting for an estimated 44.5% share in 2026.
• By organ type, kidney applications are expected to lead the market with a 32.4% share in the 2026.
• In terms of end users, hospitals and surgical centers constitute the largest segment, representing approximately 34.6% of the global market in 2026.
• North America is expected to lead the market, holding a share of 41.4% in 2026.
• Asia Pacific is anticipated to be the fastest-growing region, with 23.5% share in 2026.

Market Overview

• The market trend highlights a strong shift towards improved organ viability and extended preservation times enabled by normothermic machine perfusion technology.
• Increasing demand for organ transplantation, rising cases of organ failure, and enhancement in healthcare infrastructure in emerging economies are key factors propelling market growth.
• Moreover, integration of real-time monitoring systems within perfusion devices and growing investment in R&D for innovative solutions further underscore the market’s dynamic evolution and promising future outlook.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Why Does Organ Preservation Lead the Global Normothermic Machine Perfusion Market in 2026?

The global normothermic machine perfusion market in application perspective is dominated by the organ preservation segment which is projected to have a market share of 44.5% in 2026. The reason for this market leader position is that organ preservation is crucial for transplanting viable organs successfully.

Normothermic machine perfusion is a new technology that directly improves on traditional methods of preserving organs. It keeps the organs at the same temperature as the human body (37 °C) and at the same condition as the human blood for up to a week, thus, and very significantly, preventing ischemic injury, allowing the organ to keep its functional and physiological activities, extending the organ storage time, which all are vital for improved transplant outcomes.

In March 2025, Paragonix Technologies, a leader in organ transplant technologies, launched a nationwide distribution fleet. This initiative aims to ensure transplant centers and organ procurement organizations (OPOs) have timely access to its organ preservation products. The first fleet vehicles will operate in Florida and California, supporting transplant programs in those regions. Paragonix’s SherpaPak Cardiac Transport System, U.S. FDA-cleared and CE-marked, has supported over 18,000 transplants.

Source: https://www.paragonixtechnologies.com/news/paragonix-announces-worlds-first-in-human-use-of-kidneyvault-renal-perfusion-system

What Drives the Dominance of the Kidney Segment in the Normothermic Machine Perfusion Market?

The kidney segment is expected to hold the highest market share in the global normothermic machine perfusion market with a share of 32.4% in 2026. This predominance is directly related to the global high incidence of kidney failure and the desperate need to make transplantation of kidney grafts more successful. Kidneys are the most frequently transplanted organs in the world, and if there are delays or damage during the preservation process, it can drastically affect their functionality after transplantation.

The demand for kidneys for transplantation is supported by normothermic machine perfusion for kidney preservation as it decreases the ischemic injury, provides for an instant assessment of organ condition, and also makes it possible to treat previously rejected marginal kidneys.

Hospitals and Surgical Centers Lead Normothermic Machine Perfusion Market

Hospitals and surgical centers represent the largest share of the normothermic machine perfusion market, with a projected 34.6% share in 2026, since they are the major players in organ transplantation surgeries and the perioperative care. They are the institutions where the most complex organ transplants are performed and thus, they render themselves as the most important stakeholders in the successful deployment of normothermic machine perfusion technologies.

Equipped with advanced medical devices, cold storage units, and perfusion machines, hospitals and surgical centers offer an integrated environment for preoperative organ preservation, real-time organ assessment, and transplant procedures. Their multidisciplinary teams and specialized expertise are key to implementing and managing these technologies effectively.

Reimbursement & Funding Landscape for Normothermic Machine Perfusion Technologies

• Reimbursement for normothermic machine perfusion (NMP) is still patchy, because payment usually sits inside broader transplant bundles. In many markets, hospitals recover costs through organ acquisition budgets, transplant DRGs, or negotiated add-ons, not a clean “NMP line item.” That forces programs to justify NMP via measurable outcomes: higher organ utilization, fewer discards, fewer ICU days, fewer complications. Where payers accept that logic, NMP is funded as a cost-offset tool, not a premium feature.
• Funding is therefore driven by transplant-center economics and policy priorities more than standard fee schedules. Early adoption is often underwritten by capital budgets, philanthropy, research grants, public innovation funds, and industry-supported clinical studies.
• The most bankable pathway is value-based contracting: pay-per-use, per-organ pricing, risk-share on utilization or outcomes, and service-inclusive leases. Expect reimbursement to improve first in kidney and liver pathways, once national bodies lock in “evidence + budget impact” thresholds.

Regional Insights

To learn more about this report, Download Free Sample

North America Normothermic Machine Perfusion Market Analysis and Trends

The North America is projected to hold the largest share of the global normothermic machine perfusion market with a 41.4% share in 2026, because of its strong healthcare infrastructure. Besides, the high usage of the latest medical technologies and the presence of the leading bioscience and medical device companies are also contributing factors to North America's dominance of the global normothermic machine perfusion market. The U.S. is the largest contributor in the region and it takes advantage of substantial investments in organ transplantation research together with government policies that favor the use of transplantation programs and innovative perfusion techniques.

The comprehensive reimbursement framework for organ preservation devices also rewards healthcare providers for adopting normothermic machine perfusion technology. Additionally, the strong presence of industry key players such as OrganOx, TransMedics, and Medtronic drives the continuous development and marketing of state-of-the-art perfusion devices.

In August 2025, a groundbreaking comparative study presented at the World Transplant Congress in California, U.S showed that Hypothermic Oxygenated Machine Perfusion (HOPE) with the VitaSmart Machine Perfusion System offers better outcomes in liver transplantation compared to Normothermic Machine Perfusion (NMP). The study revealed improved organ and recipient survival with fewer post-transplant complications, including reduced non-anastomotic strictures (NAS) and NAS-associated graft loss.

(Sources:https://bridgetolife.eu/bridge-to-life-unveils-groundbreaking-12-month-clinical-trial-data-on-hope-at-world-transplant-congress-2025-2/)

Asia Pacific Normothermic Machine Perfusion Market Analysis and Trends

Asia Pacific will be the fastest developing part of the world with a share of 23.5% in 2026, as improving healthcare infrastructure, the increasing rates of organ transplantation, and the growing awareness of the benefits of organ preservation are the main factors for the market's growth. The rapid increase of the population in urban areas and both government and private sector investments in upgrading transplant facilities are the main reasons for the market expansion.

China, India, Japan, and South Korea are some countries that are experiencing vast amounts of research and development investing in the area of creating affordable and user-friendly perfusion devices that are fit for their varied patient populations. Market growth is driven by several companies, including subsidiaries of global players and emerging local startups, that are tackling the difficult issues of organ availability and transplant wait times.

Normothermic Machine Perfusion Market Outlook for Key Countries

What are the Key Trends in the U.S. Normothermic Machine Perfusion Market?

The U.S. leads the normothermic machine perfusion market with widespread clinical acceptance and the presence of a large organ transplantation network. Market leaders like OrganOx and TransMedics have heavily invested in R&D and clinical trials in the U.S., driving technological advancements.

The government's proactive stance on organ donation policies, coupled with substantial funding for transplantation research, has accelerated adoption. Collaborations between device manufacturers and top-tier medical institutions further enhance the country's role as a key innovator and adopter of normothermic machine perfusion systems.

What are the Latest Market Dynamics Influencing Normothermic Machine Perfusion Adoption in Germany?

In Europe, Germany is still a key market backed by the excellent healthcare system, advanced transplantation programs, and supportive regulations for innovative medical devices. Besides Medtronic and Organ Assist, other important companies have a relatively strong presence in Germany and are offering perfusion technologies that comply with the European clinical standards.

Germany, besides giving priority to the quality of patient care, is also proactive in conducting organ procurement campaigns, which are necessary for new technologies to be adopted. Furthermore, Germany is endowed with transplant registries which are already in place and is implementing reimbursement processes that are hospital-friendly, thus, ensuring that hospitals are encouraged to adapt to normothermic machine perfusion solutions.

China Normothermic Machine Perfusion Market Trends

The normothermic machine perfusion market in China is on the rise due to the increasing government measures to open up the organ transplant field as well as improving the outcome of post-transplantation. The modernization of the Chinese healthcare system along with the rising awareness of the benefits of organ transplantation and the setting up of organ donation networks are the factors hastening the market growth.

Local firms and giant multinational companies competing on a similar footing both are developing custom-made innovations for a huge customer that is China.

Japan Normothermic Machine Perfusion Market Trends

Japan remains at the forefront in Asia Pacific with regard to the adoption of normothermic machine perfusion for its advanced healthcare system and a strong focus on regenerative medicine and transplantation research. The Japanese companies are in very close cooperation with the global technology providers, making the perfusion systems according to the requirement of local clinics.

The inclusion of novel transplantation techniques under national health insurance increases their economic viability. Japan’s prioritization of organ preservation technology is in line with its overall plan of prolonging organ viability to succeed in transplants, which is further supported by scientific cooperation and the high standards of healthcare.

End User Feedback and Unmet Needs in the Normothermic Machine Perfusion Market

• End user feedback from transplant centers and organ procurement organizations is largely positive, with clinicians valuing the ability of normothermic machine perfusion to assess organ viability in real time and safely use marginal organs. Users report improved confidence in transplant decisions, better preservation during transport, and higher utilization rates, particularly in liver and kidney programs. A frequently cited success case is the recovery and transplantation of organs that would previously have been discarded, directly improving waitlist outcomes.
• However, adoption is constrained by high costs, operational complexity, and limited reimbursement clarity. Smaller centers highlight challenges around staffing, training, and workflow integration. Key unmet needs include more affordable and flexible pricing models, easier-to-use systems, and standardized protocols across organs. Addressing these gaps can drive wider adoption, strengthen customer retention, and push innovation toward simpler, outcome-linked, and service-oriented NMP solutions.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In March 2025, OrganOx Ltd., a pioneering organ technology company, partnered with ProCure On-Demand, a U.S. organ recovery service provider. The collaboration aims to enhance liver transplant efficiency by combining OrganOx’s normothermic machine perfusion (NMP) technology with ProCure’s surgical and logistical solutions. This partnership will support transplant centers with additional clinical services, improving organ recovery and patient outcomes.
• In February 2024, Mount Sinai Recanati/Miller Transplantation Institute received a USD 5 million gift from the Blavatnik Family Foundation. This donation will support the expansion of normothermic machine perfusion technology, aimed at improving organ viability for transplantation. The first part of the gift will establish an international organ registry to advance perfusion efforts and explore AI applications for better organ quality prediction.
• In July 2023, Ochsner Health System published a new study in Annals of Surgery showing the potential benefits of normothermic machine perfusion (NMP) in liver transplantation. The trial, conducted across 15 liver transplant centers, compared NMP, which maintains the organ at normal body temperature, with static cold storage (SCS) in 383 donor livers.

Top Strategies Followed by Global Normothermic Machine Perfusion Market Players

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Report Scope

Normothermic Machine Perfusion Market Report Coverage

Normothermic Machine Perfusion Market Dynamics

Normothermic Machine Perfusion Market Driver - Rising Demand for Organ Transplants due to Chronic Disease

The rising incidence of chronic diseases like diabetes, cardiovascular disorders, and chronic kidney disease has been the main reason behind the ever-increasing demand for organ transplants all over the world. These diseases are usually the cause of organ failure, hence the need for the effective preservation and evaluation methods to ensure the maximum viability of the donor organ.

Normothermic machine perfusion (NMP) has become a significant technology, which is able to providing the highest level of preservation by keeping the organs at body temperatures and supplying them with oxygenated blood. The method is very effective in cutting down ischemic injury and hence boosting the rates of transplant success.

In March 2025, India reached a milestone of 18,900 organ transplants, with Health Minister J.P. Nadda emphasizing the importance of strengthening the organ donation ecosystem. The country now ranks third globally for transplants and leads in hand transplants. Notable government initiatives include the Aadhaar-based NOTTO platform, which has gathered over 3.3 lakh organ pledges.

Source: https://ddnews.gov.in/en/india-achieves-record-18900-organ-transplants-in-2024-health-minister-j-p-nadda/

Normothermic Machine Perfusion Market Opportunity - Development of Portable and Compact NMP Devices for Field and Remote Use

The advent of portable normothermic machine perfusion (NMP) devices represents a major growth opportunity. The new devices tackle the disadvantages posed by traditional, heavy and bulky perfusion systems. They make it possible to preserve organs and check their viability in far-off places with little or no medical infrastructure.

The miniaturization, the use of lighter materials, and the development of energy-efficient technologies have made the NMP devices much more mobile and user-friendly. The progress in this area not only assures immediate action during the organ recovery and transport but also enhances the chances for organ acceptance at the transplant site.

Another example is XVIVO, which has focused on miniaturizing its perfusion systems, making them suitable for field and remote use. Their products, including the XVIVO Perfusion System, enhance mobility and efficiency in organ preservation, addressing key challenges in organ transportation. These advancements in portability are crucial for improving healthcare accessibility in underserved regions and optimizing organ transplant logistics globally.

Source: https://www.xvivogroup.com/organ-perfusion/

Analyst Opinion (Expert Opinion)

• The normothermic machine perfusion market is experiencing a speedy growth resulting from the advances in portable and compact devices that promised better organ preservation. The growth is attributed to the key factors of increasing transplant demand, technological innovations, and regulatory support. The organ viability is effectively improved during transportation especially in remote places due to the use of miniaturized devices with smart sensors, whereas investment from both the public and private sectors is promoting the market adoption.
• Recent conferences such as Transplantation Society’s annual congress have helped NMP technology enormously through global collaboration. U.S. government partnerships with private firms and pilot programs in the U.S. and U.K. are hitting the market with innovations and better transplant outcomes continuously shaping the organ preservation future.

Market Segmentation

• Application Insights (Revenue, USD Bn, 2021 - 2033)
  • Organ Preservation
  • Organ Reconditioning
  • Organ Transplantation
• Organ Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Kidney
  • Liver
  • Heart
  • Lung
  • Pancreas
• End User Insights (Revenue, USD Bn, 2021 - 2033)
  • Hospitals and Surgical Centers
  • Organ Transplantation Centers
  • Research Laboratories
  • Organ Procurement Organizations
• Type of Perfusion Insights (Revenue, USD Bn, 2021 - 2033)
  • Hypothermic Machine Perfusion
  • Normothermic Machine Perfusion
• Component Insights (Revenue, USD Bn, 2021 - 2033)
  • Consumables (Tubing, Solution Kits, Filters)
  • Devices (Perfusion Machines, Sensors)
  • Software (Monitoring and Data Analysis Systems)
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • TransMedics Group Inc
  • Organ Recovery Systems
  • XVIVO Perfusion AB
  • OrganOx Limited
  • Getinge (Paragonix Technologies)
  • Bridge to Life Ltd
  • Waters Medical Systems
  • Preservation Solutions Inc
  • Institut Georges Lopez SA
  • EBERS Medical Technology SL
  • Shenzhen Lifotronic Technology Co Ltd
  • Genus Medical Technologies LLC
  • Terumo Corporation
  • Medtronic plc
  • LivaNova Plc

Sources

Primary Research Interviews

• Industry Stakeholders List
• Organ Procurement Organizations (OPOs)
• Transplant Centers and Surgeons
• End users List
• Hospitals with Transplantation Units
• Surgical Centers specializing in Organ Transplantation

Government and International Databases

• U.S. Department of Health and Human Services (HHS)
• World Health Organization (WHO)
• European Medicines Agency (EMA)
• U.S. Food and Drug Administration (FDA)
• National Institutes of Health (NIH)
• The Organ Procurement and Transplantation Network (OPTN)

Trade Publications

• Transplantation Proceedings
• American Journal of Transplantation
• Journal of Organ Donation & Transplantation
• Clinical Transplantation
• Transplantation Direct
• Organ Preservation Technologies Journal

Academic Journals

• Annals of Surgery
• The Lancet
• Journal of Clinical Investigation
• Nature Biotechnology
• Cell Transplantation
• The American Journal of Surgery

Reputable Newspapers

• The New York Times
• The Washington Post
• The Guardian
• The Wall Street Journal
• Financial Times
• USA Today

Industry Associations

• American Society of Transplantation (AST)
• The Transplantation Society (TTS)
• European Society for Organ Transplantation (ESOT)
• National Kidney Foundation (NKF)
• International Society for Organ Donation and Procurement (ISODP)
• American Society of Transplant Surgeons (ASTS)

Public Domain Resources

• National Institutes of Health (NIH) ClinicalTrials.gov
• U.S. National Library of Medicine (PubMed)
• Organ Donation and Transplantation Collaborative (ODTC)
• National Organ Transplant Act (NOTA)
• European Union Public Health Portal
• National Heart, Lung, and Blood Institute (NHLBI)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years